195P - The prevalence and clinical characteristics of ALK and ROS1 fusions in East Asian patients with non-small cell lung cancer

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Biomarkers
Non-Small-Cell Lung Cancer, Metastatic
Presenter Weijing Cai
Authors W. Cai1, C. Zhou2, S. Ren3, X. Chen3, X. Li2
  • 1Shanghai Pulmonary Hospital, Shanghai/CN
  • 2Lung Cancer Institute, Shanghai Pulmonary Hospital, 200433 - Shanghai/CN
  • 3Oncology Department, Shanghai Pulmonary Hospital, Shanghai/CN

Abstract

Background

ALK and ROS1 fusions have been proven to be oncogenic drivers in some subsets of lung cancer. The prevalence of ALK and ROS1 fusions in East Asian patients with non-small cell lung cancer (NSCLC) remains unclear.

Objective

To determine the prevalence and clinical characteristics of ALK and ROS1 fusions in East Asian patients with NSCLC.

Patients and Methods

We screened 304 biopsied or surgically resected specimens from patients with histologically confirmed NSCLC for EML4-ALK and ROS1 fusions using multiplex RT-PCR and validated all positive samples by Sanger sequencing. The patterns of ROS1 fusions involved in this study contained CD74-ROS1 and SLC34A2-ROS1.

Results

Of these 304 patients with NSCLC screened, 246 had adenocarcinoma, 21 had adenosquamous and 35 had squamous cell lung cancer, with the male to female ratio of about 1:3 and median age of about 59 years. 89.8% of patients were never or light smokers. Patients with stage I, II, III or IV disease at diagnosis accounted for 47.2%, 11.3%, 33.3% and 8.2%, respectively. The data of EML4-ALK fusion test were available on all the 304 patients, with an incidence of about 8.2%. The data of ROS1 fusion test were available on 195 patients so far, with overall incidence of 3.0%. The relationship between EML4-ALK and ROS1 fusions and clinical characteristics will be presented at the conference.

Conclusion

The EML4-ALK and ROS1 fusions are quite rare events, with the prevalence of about 8.2% and 3.0% in East Asian patients with NSCLC, respectively. The data of clinical characteristics will be presented at the congress.

Disclosure

All authors have declared no conflicts of interest.